Form 4: Adaptive Biotechnologies' Chief Scientific Officer Exercises Options and Sells Shares Under 10b5-1 Plan

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 1, 2025, Harlan S Robins, the Chief Scientific Officer of Adaptive Biotechnologies, exercised stock options to acquire 68,412 shares of common stock at a price of $6.32 per share.
• Simultaneously, Robins sold 68,412 shares of common stock at a weighted-average price of $7.35 per share, with individual sales ranging from $7.18 to $7.51.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 26, 2024.
• Following these transactions, Robins beneficially owns 1,279,524 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, which doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant way for insiders to manage their stock holdings.

Risks

• While the transactions are part of a pre-arranged plan, significant insider selling could be perceived negatively by the market if misinterpreted.

Industry Context

Insider transactions are common, and the use of a 10b5-1 plan suggests a structured approach to managing personal investments without the appearance of acting on non-public information. Investors often monitor insider activity for signals about a company's prospects, but pre-planned sales are generally less informative.

Comparison to Industry Standards

• Comparing the weighted average sale price of $7.35 to the trading prices of similar biotechnology companies at the time could provide context on whether the sale was executed at a fair market value.
• Companies like Illumina or Pacific Biosciences could be used as benchmarks for evaluating Adaptive Biotechnologies' stock performance and insider trading activity.

Stakeholder Impact

• The transactions could have a minor impact on shareholders if the market interprets the insider selling negatively, although the existence of a 10b5-1 plan mitigates this risk.

Key Dates

Keywords

Adaptive Biotechnologies, insider trading, Form 4, stock options, Rule 10b5-1, Harlan S Robins, ADPT